Kenvue Inc. Common Stock (KVUE)

Both of these healthcare leaders are Dividend Kings.

Johnson & Johnson's new drugs may offset declining sales due to patent-protection losses.

Hsu discusses tariff refunds, China disruptions, and Kenvue integration plans.

As stocks pull back from recent highs, lean into these three blue chip dividend stocks.

A name that's often ignored by investors due to its limited historic growth is evolving into a solid income-growth prospect.

This Dividend King just made a major strategic pivot.

J&J has more than 28 sources of blockbuster revenue.

Griffin is at the helm of the world's most profitable hedge fund.

History says SpaceX stock could fall much further during its first year on the market.

Kimberly-Clark is far from flashy, but what it lacks in glitz and glam, it makes up for with predictability.

These stocks have long histories of growing their payouts to shareholders.

Colgate-Palmolive continues to deliver solid results despite a slew of industry challenges.

These three healthcare stocks provide stability, relatively high dividend yields, and consistent growth.

SpaceX has fallen sharply from its post-IPO peak, but history says the stock will drop much further in the months ahead.

These three overlooked dividend stocks combine durable brands, rising payouts, and long-term growth potential for investors focused on building wealth over the next decade.

In an unstable market, these three companies offer investors a chance to own durable consumer businesses that generate steady growth regardless of economic headlines.

Kenvue offers both a great short-term and long-term payoff to investors.

SpaceX topped $2 trillion on its first trading day, but history says the stock will drop sharply in the next year.

When stock prices go down, dividend yields go up.

Historically, large IPO stocks have often declined during their first year on the public market.

These stocks may deliver gains during any market environment.